Quick Answer
Arcus Biosciences, Inc. reported Stockholders Equity of $631.00 million for the year ending 2025.
- Arcus Biosciences, Inc. showed an increase of +30.1% in Stockholders Equity from 2024 to 2025.
- This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $266.59 million | Q2 2018: $254.57 million | Q3 2018: $245.12 million | Q1 2019: $221.57 million | Q2 2019: $196.65 million | Q3 2019: $177.23 million | Q1 2020: $140.64 million | Q2 2020: $428.71 million | Q3 2020: $544.42 million | Q1 2021: $664.79 million | Q2 2021: $604.56 million | Q3 2021: $542.61 million | Q1 2022: $797.00 million | Q2 2022: $747.00 million | Q3 2022: $699.00 million | Q1 2023: $600.00 million | Q2 2023: $566.00 million | Q3 2023: $520.00 million | Q1 2024: $707.00 million | Q2 2024: $635.00 million | Q3 2024: $565.00 million | Q1 2025: $531.00 million | Q2 2025: $549.00 million | Q3 2025: $436.00 million.
- Over the full 11 years of available data (2015 to 2025), Arcus Biosciences, Inc.'s Stockholders Equity has grown by 29,164.9%.
- Historical annual values: Fiscal year 2025: $631.00 million | Fiscal year 2024: $485.00 million | Fiscal year 2023: $462.00 million | Fiscal year 2022: $657.00 million | Fiscal year 2021: $842.00 million | Fiscal year 2020: $502.00 million | Fiscal year 2019: $164.00 million | Fiscal year 2018: $234.94 million | Fiscal year 2017: -$72.33 million | Fiscal year 2016: -$19.99 million | Fiscal year 2015: -$2.17 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: